RxDoctor Payments DataLook up a doctor →

Mark Saslawsky, MD

Urology · Memphis, TNNPI 1184739401

Payments from drug & device makers

$32,580in general payments, 2019–2025

Across 675 payments — averaging $48.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$9K
  • Johnson & Johnson$5K
  • Urogen Pharma, Inc.$4K
  • Dendreon Pharmaceuticals LLC$2K
  • Astellas Pharma US Inc$1K
  • Ferring Pharmaceuticals Inc.$1K
  • plus $11K from 46 others

What the payments were for

  • Consulting fees$8,03025%
  • Speaking & faculty fees$2,1467%
  • Travel & lodging$1,2214%
  • Food & beverage$20,78764%
  • Education$3981%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,580 in reported general payments places this provider in the 85th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$870,888
Medicare patients
787
Services billed
9,466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide340$4,629,842
ErleadaApalutamide120$1,745,558
XgevaDenosumab68$212,801
OrgovyxRelugolix80$204,710
NubeqaDarolutamide12$144,062
ProliaDenosumab23$39,483
MyrbetriqMirabegron43$38,723
GemtesaVibegron23$17,422
EligardLeuprolide Acetate12$15,312
Tamsulosin Hcl557$8,146
Finasteride475$7,747
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl17$3,846
Trospium Chloride ErTrospium Chloride13$3,121
Dutasteride104$2,654
Oxybutynin Chloride ErOxybutynin Chloride122$2,536

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,265$4,668,565383 claims
Johnson & JohnsonErleada$5,075$1,745,558120 claims
AmgenXgeva, Prolia$118$252,28491 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$374$222,132103 claims
BayerNubeqa$866$144,06212 claims
Tolmar Pharmaceuticals, Inc.Eligard$676$15,31212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 276 urology providers in Tennessee.

Other urology in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →